OHSU's CNS disorder drug developer has launched with $76m from investors co-led by Arch Venture Partners and Cowen Healthcare Investments.

Stanford’s lysosome protein degradation spinout Lycia emerged with $50m of capital from Versant Ventures to develop a portfolio of drug candidates.

Varian Medical Systems and Johnson & Johnson Innovation – JJDC have returned for the series C-1 round having backed the U-M spinout's series C last year.

WSU neurodegenerative disease drug spinout Athira Pharma will put the proceeds towards phase 2/3 clinical testing of a treatment for Alzheimer's disease.

Illumina, General Atlantic and Viking Global have supplied $70m for Ginkgo Bioworks, an MIT spinout that has now raised more than $789m altogether.

Q32 Bio has launched with $46m from investors including University of Colorado to target autoimmune and inflammatory diseases.

MIT's fusion energy spinout Commonwealth Fusion Systems secured the return of The Engine and Eni for a $84m series A2 round that followed a $115m series A last year.

Novo has led a $60m series C round for University of Dundee’s Exscientia that also attracted Evotec, Bristol-Myers Squibb, and GT Healthcare Capital.

Stanford’s proteomic analysis spinout has lifted its funding haul beyond $100m with a round set to drive new hires and technology development.

Oxford Nanopore has added $59.6m to its latest funding round to bring the round to $98.1m and its overall funding to nearly $692m.